PDCD1 and non-small cell lung carcinoma: For example, a significant improvement of progression-free survival (and higher overall response rates were observed in patients with non-small cell lung carcinoma (NSCLC) treated with anti PD-1 (pembrolizumab) plus chemotherapy [4,5].